|Other names||Sarcoma family syndrome of Li and Fraumeni|
|Li–Fraumeni syndrome is inherited via an autosomal dominant manner|
|Specialty||Oncology, Medical genetics, Endocrinology|
Li–Fraumeni syndrome is a rare, autosomal dominant, hereditary disorder that pre-disposes carriers to cancer development. It was named after two American physicians, Frederick Pei Li and Joseph F. Fraumeni, Jr., who first recognized the syndrome after reviewing the medical records and death certificates of 648 childhood rhabdomyosarcoma patients. This syndrome is also known as the sarcoma, breast, leukaemia and adrenal gland (SBLA) syndrome.
The syndrome is linked to germline mutations of the p53 tumor suppressor gene, which encodes a transcription factor (p53) that normally regulates the cell cycle and prevents genomic mutations. The mutations can be inherited, or can arise from mutations early in embryogenesis, or in one of the parent's germ cells.
Li–Fraumeni syndrome is characterized by early onset of cancer, a wide variety of types of cancers, and development of multiple cancers throughout one's life.
This section needs additional citations for verification. (February 2016) (Learn how and when to remove this template message)
LFS1: Mutations in TP53
- Normal Conditions: TP53 is a tumor suppressor gene on chromosome 17 that normally assists in the control of cell division and growth through action on the normal cell cycle. TP53 typically become expressed due to cellular stressors, such as DNA damage, and can halt the cell cycle to assist with either the repair of repairable DNA damage, or can induce apoptosis of a cell with irreparable damage. The repair of "bad" DNA, or the apoptosis of a cell, prevents the proliferation of damaged cells.
- Mutant Conditions: Mutations of TP53 can inhibit its normal function, and allow cells with damaged DNA to continue to divide. If these DNA mutations are left unchecked, some cells can become immortalized, and divide in an uncontrolled manner forming tumors (cancers). Further mutations in the DNA could lead to malignant cells that can travel to, and develop cancer in different areas of the body. Many individuals with Li–Fraumeni syndrome have been shown to be heterozygous for a TP53 mutation. Recent studies have shown that 60% to 80% of classic LFS families harbor detectable germ line TP53 mutations, the majority of which are missense mutations in the DNA-binding domain. These missense mutations cause a decrease in the ability of p53 to bind to DNA, thus inhibiting the normal TP53 mechanism.
- Unique Brazilian Mutation: Although other mutations leading to Li–Fraumeni syndrome have been found outside the DNA-binding domain, a mutation at codon 337 of the tetramerization domain of TP53 has shown a particularly high frequency. The tetramerization domain plays a major role in the oligomerization of the p53 protein, which exists as a tetramer. This mutation has only been found in Brazilian families, and is located in exon 10 of the TP53 gene. The mutation causes an amino acid change from arginine to histidine at codon 337. With pH in the low to normal physiological range (up to 7.5), the mutant protein forms normal oligomers and retains its suppressor function. However, at a high physiological pH, p53 is unable to assemble into a tetramer. This unique feature may contribute to why families with this particular mutation often show incomplete penetrance.
- Dominant Negative Mutations: Most individuals with Li–Fraumeni syndrome are heterozygous for a mutant TP53 gene, and some p53 mutants can inhibit the function of the wild-type p53 in a dominant negative manner. Mutated p53 proteins are typically more stable than wild-type, and can inhibit the activity of the wild-type protein in suppressing cell proliferation and in inducing cell cycle arrest. Due to the mutant p53 being able to inhibit some wild-type p53, damaged cells are at an even greater susceptibility to proliferate and become transformed, resulting in cancer.
LFS2: Mutations in CHEK2
Another variant of Li–Fraumeni that remains somewhat controversial, is a mutation of the CHEK2 (or CHK2) gene. CHK2 is also a tumor suppressor gene. CHK2 regulates the action of p53. CHK2 is activated by ATM which detects DNA damage, and in this way DNA damage information can be conveyed to p53 to indirectly arrest the cell cycle at that point for DNA repair to be able to take place or to cause apoptosis (programmed cell death).
Families that do not conform to the criteria of classical Li–Fraumeni syndrome have been termed "LFS-like". LFS-like individuals generally do not have any detectable p53 mutations, and tend to be diagnosed on either the Birch or Eeles criteria.
The classical LFS malignancies - sarcoma, cancers of the breast, brain and adrenal glands - comprise about 80% of all cancers that occur in this syndrome.
The risk of developing any invasive cancer (excluding skin cancer) is ~50% by age 30 (1% in the general population) and is 90% by age 70. Early onset breast cancer accounts for 25% of all the cancers in this syndrome. This is followed by soft tissue sarcomas (20%), bone sarcoma (15%) and brain tumors - especially glioblastomas - (13%). Other tumours seen in this syndrome include leukemia, lymphoma and adrenocortical carcinoma.
~90% of females with LFS develop breast cancer by age 60 years; the majority of these occur before age 45 years. Females with this syndrome have almost a 100% lifetime risk of developing cancer. This compares with 73% for affected males. The difference may be due to much smaller breast tissue in males as well as increased estrogen levels in females.
The risks of sarcoma, female breast cancer and haematopoietic malignancies in mutation carriers are more than 100 times greater than those seen in the general population.
Other tumours reported in this syndrome but not yet proved to be linked with it include melanoma, Wilm's and other kidney tumors, hepatacellular carcinoma, gonadal germ cell, pancreatic, gastric, choroid plexus, colorectal and prostate cancers.
Although most cases of this syndrome have early onset of cancer, cases have also been reported later in life.
Li–Fraumeni syndrome is diagnosed if the following three criteria are met:
- the patient has been diagnosed with a sarcoma at a young age (below 45),
- a first-degree relative has been diagnosed with any cancer at a young age (below 45), and
- another first-degree or a second-degree relative has been diagnosed with any cancer at a young age (below 45) or with a sarcoma at any age.
Other criteria have also been proposed:
- a proband with any childhood cancer or sarcoma, brain tumor or adrenal cortical carcinoma diagnosed before age 45
- a first or second degree relative with a typical LFS malignancy (sarcoma, leukaemia, or cancers of the breast, brain or adrenal cortex) regardless of age at diagnosis
- a first or second degree relative with any cancer diagnosed before age 60.
A third criterion has been proposed
- two first or second degree relatives with LFS-related malignancies at any age.[verification needed]
Genetic counseling and genetic testing are used to confirm that somebody has this gene mutation. Once such a person is identified, early and regular screenings for cancer are recommended for him or her as people with Li–Fraumeni are likely to develop another primary malignancy at a future time (57% within 30 years of diagnosis).
A 2015 revision of the traditional Chompret criteria for screening has been proposed:
A proband who has:
- a tumor belonging to LFS tumor spectrum (e.g., premenopausal breast cancer, soft tissue sarcoma, osteosarcoma, CNS tumor, adrenocortical carcinoma) before age 46 years, AND at least one first or second-degree relative with LFS tumor (except breast cancer if proband has breast cancer) before age 56 years or with multiple tumors at any age; OR
- multiple tumors (except multiple breast tumors), two of which belong to LFS spectrum with the initial cancer occurring before the age of 46 years; OR
- an adrenocortical carcinoma, choroid plexus tumor, or rhabdomyosarcoma of embryonal anaplastic subtype, at any age of onset, irrespective of family history; OR
- breast cancer before age 31
This section does not cite any sources. (February 2016) (Learn how and when to remove this template message)
Recommendations for individuals from families affected by the syndrome include:
- Avoidance of radiation therapy to reduce risk of secondary radiation induced malignancies,
- Children and adults undergo comprehensive annual physical examination,
- Women undergo age specific breast cancer monitoring beginning at age 25 years, and
- All patients should consult a physician promptly for evaluation of lingering symptoms and illnesses.
- Adults undergo routine screening for colorectal cancer beginning no later than age 25 years
- Individuals undergo organ targeted surveillance based on the pattern of cancer observed in their family
Prophylactic mastectomy to reduce the risk of breast cancer is an option.
Li–Fraumeni syndrome (LFS) is relatively rare;[clarification needed] as of 2011, cases had been reported in more than 500 families. The syndrome was discovered using an epidemiological approach. Li and Fraumeni identified four families in which siblings or cousins of rhabdomyosarcoma patients had a childhood sarcoma, which suggested a familial cancer syndrome. Identification of TP53 as the gene affected by mutation was suggested by the same approach. Over half of the cancers in Li-Fraumeni families had been previously associated with inactivating mutations of the p53 gene and in one primary research study, DNA sequencing in samples taken from five Li–Fraumeni syndrome families showed autosomal dominant inheritance of a mutated TP53 gene.[non-primary source needed]
- Custódio G; et al. (July 2013). "Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors". J. Clin. Oncol. 31 (20): 2619–26. doi:10.1200/JCO.2012.46.3711. PMC 3808236. PMID 23733769.
- Li F.P.; Fraumeni J.F. (October 1969). "Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?". Ann. Intern. Med. 71 (4): 747–52. doi:10.7326/0003-4819-71-4-747. PMID 5360287.
- Varley J.M. (March 2003). "Germline TP53 mutations and Li-Fraumeni syndrome". Hum. Mutat. 21 (3): 313–20. doi:10.1002/humu.10185. PMID 12619118.
- Hisada, M.; Garber, J. E.; Li, F. P.; Fung, C. Y.; Fraumeni, J. F. (1998). "Multiple Primary Cancers in Families With Li-Fraumeni Syndrome". Journal of the National Cancer Institute. 90 (8): 606–611. doi:10.1093/jnci/90.8.606.
- Malkin, D. (2011). "Li-Fraumeni Syndrome". In Levine, Arnold J. (ed.). Genes and Cancer. Genes & Cancer. 2. pp. 475–484. doi:10.1177/1947601911413466. PMC 3135649. PMID 21779515.
- Chène, P. (2001). "The Role of Tetramerization in p53 function" (online, print review). Oncogene. 20 (21): 2611–2617. doi:10.1038/sj.onc.1204373. PMID 11420672.
- Willis, Amy; Jung, Eun Joo; Wakefield, Therese; Chen, Xinbin (2004). "Mutant p53 Exerts a Dominant Negative Effect by Preventing Wild-Type p53 from Binding to the Promoter of its Target Genes". Oncogene. 23 (13): 2330–2338. doi:10.1038/sj.onc.1207396. PMID 14743206. Retrieved 22 February 2016.[non-primary source needed]
- Chan SH, Lim WK, Michalski ST, Lim JQ, Ishak NDB, Met-Domestici M, Young CNC, Vikstrom K, Esplin ED, Fulbright J, Ang MK, Wee J, Sittampalam K, Farid M, Lincoln SE, Itahana K, Abdullah S, Teh BT, Ngeow J (2016) Germline hemizygous deletion of CDKN2A-CDKN2B locus in a patient presenting with Li-Fraumeni syndrome. NPJ Genom Med 1:16015. doi: 10.1038/npjgenmed.2016.15.
- Cho, Yonggeun; Kim, Juwon; Kim, Yoonjung; Jeong, Joon; Lee, Kyung-A (2013). "A Case of Late-Onset Li-Fraumeni-like Syndrome with Unilateral Breast Cancer". Annals of Laboratory Medicine. 33 (3): 212–6. doi:10.3343/alm.2013.33.3.212. PMC 3646199. PMID 23667851.[non-primary source needed]
- Birch JM, Hartley AL, Tricker K, Prosser J, Condie A, Kelsey A, Harries M, Jones P, Binchy A, Crowther D, Craft A, Eden O, Evans D, Thompson E, Mann J, Martin J, Mitchell E, Santibanez-Koref M (1994). "Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families". Cancer Research. 54 (5): 1298–304. PMID 8118819.[non-primary source needed]
- Eeles, R. (1995). "Germline mutations in the TP53 gene". Cancer Surveys. 25: 101–124. PMID 8718514.
- Bougeard, G., Renaux-Petel, M., Flaman, J. M., Charbonnier, C., Fermey, P., Belotti, M., … Frebourg, T. (2015). Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. Journal of Clinical Oncology, 33(21), 2345–2352. https://doi.org/10.1200/JCO.2014.59.5728
- Malkin, D.; Li, F.P.; Strong, L.C.; Fraumeni Jr, J.F.; Nelson, C.E.; Kim, D.H.; Kassel, J.; Gryka, M.A.; Bischoff, F.Z. Tainsky, M.A.; et al. (1990). "Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms". Science. 250 (4985): 1233–1238. doi:10.1126/science.1978757. PMID 1978757.CS1 maint: Multiple names: authors list (link)[non-primary source needed]
- Malkin D. & Friend, S.H. (1993). "Correction: a Li-Fraumeni syndrome p53 mutation. Erratum for "Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms"". Science. 259 (5097): 878. doi:10.1126/science.8438145. PMID 8438145.
- Li-Fraumeni Syndrome Association (LFS Association / LFSA) is a non-profit, patient advocacy organization that provides patient and research support, and education, globally. Reference https://www.lfsassociation.org/ for more information and resources.
- The George Pantziarka TP53 Trust is the UK Li Fraumeni Syndrome patient support and advocacy organisation.
- Li–Fraumeni syndrome, in the National Library of Medicine Genetics Home Reference (an introduction to the disease)
- Li–Fraumeni Syndrome by Katherine A Schneider and Frederick Li, in GeneReviews, a section of GeneTests, published online by the University of Washington with funds from the National Institutes of Health
- Li–Fraumeni syndrome; LFS1, entry in Online Mendelian Inheritance in Man (OMIM), published by Johns Hopkins University and the National Institutes of Health